pharma · Major Depressive Disorder (MDD) · Primary or advanced breast cancer LumA or ER+ Lobular subtypes.
Talon Biomarkers
Talion
Talion is a pharma organization headquartered in JP. Primary therapeutic focus areas include Major Depressive Disorder (MDD), Primary or advanced breast cancer LumA or ER+ Lobular subtypes., non-small cell lung cancer (N
Whippany, USA HQ
2021 Founded
7 Employees
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Whippany, USA
- Founded
- 2021
- Employees
- 7
- Programs
- 5
- Drugs
- 44
- Patents
- 0
CIBI3009A101
Phase 2 · other · Extensive-Stage Small Cell Lung Cancer
CIBI3009A101 for Extensive-Stage Small Cell Lung Cancer is a Phase 2 program (other) at Talion with 1 ClinicalTrials.gov record(s).
Internal code CIBI3009A101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Talion
- Phase
- Phase 2
- Modality
- other
- Indication
- Extensive-Stage Small Cell Lung Cancer
- Status
- active
- Trials
- 1